Carlos Abril-Pérez, Miguel Mansilla-Polo, Begoña Escutia-Muñoz, Onofre Sanmartín, Joan R Garcés, Manuel A Rodríguez-Prieto, Verónica Ruiz-Salas, Esther de Eusebio-Murillo, Román Miñano-Medrano, Beatriz González-Sixto, Juan L Artola-Igarza, Alberto Alfaro-Rubio, Pedro Redondo, Yolanda Delgado-Jiménez, Julia M Sánchez-Schmidt, Irati Allende-Markixana, María L Alonso-Pacheco, Beatriz García-Bracamonte, Pablo de la Cueva-Dobao, Raquel Navarro-Tejedor, Cristina Ciudad-Blanco, Lucía Carnero-González, Hugo Vázquez-Veiga, Natividad Cano-Martínez, Carlos Serra-Guillén, Eva Vilarrasa, Pedro Sánchez-Sambucety, José L López-Estebaranz, Ángeles Flórez-Menéndez, Antonio Martorell-Calatayud, Pilar Gil, Victoriano Morales-Gordillo, Agustí Toll, Izascun Ocerin-Guerra, Matías Mayor-Arenal, Ricardo Suárez-Fernández, Laura Sainz-Gaspar, Miguel A Descalzo, Ignacio Garcia-Doval, Rafael Botella-Estrada
BACKGROUND: Immunosuppressed (IS) patients, particularly solid organ transplant recipients and those on immunosuppressive therapy, face a higher incidence and recurrence of nonmelanoma skin cancers (NMSC), including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). Mohs micrographic surgery (MMS) is the preferred treatment for high-risk NMSC due to its high cure rate and margin examination capabilities. However, IS patients may experience more complications, such as surgical site infections, and a greater risk of recurrence, making their outcomes a subject of interest...
May 11, 2024: Journal of the European Academy of Dermatology and Venereology: JEADV